Canopy Growth Stock Faces Investor Caution Until Profitability Emerges

Profitability is the missing catalyst.

Canopy Growth hasn't reported back-to-back quarterly profits since its 2018 peak, a drought that's kept institutional investors on the sidelines. The company's most recent quarterly earnings, filed in June 2026, showed a net loss of CAD $47 million on revenue of CAD $98 million. Gross margins improved to 22% from 18% a year earlier. Operating expenses continue to outpace revenue growth.

The profitability gap isn't unique to Canopy. Across Canada's licensed producer cohort, only Tilray Brands and Organigram have posted consecutive profitable quarters in the past twelve months. Health Canada data shows the domestic market has contracted 4% year-over-year as price compression and oversupply persist.

Restructuring cut costs but hasn't reversed the bottom line.

Canopy Growth initiated a restructuring plan in fiscal 2024 that eliminated 800 positions and closed five cultivation facilities. The company reduced its workforce by 35% and trimmed annual operating costs by an estimated CAD $150 million. Despite these cuts, the company burned through CAD $62 million in cash during Q2 2026, according to its cash flow statement.

CEO David Klein said in the June earnings call that the company expects to reach adjusted EBITDA breakeven by Q4 2026, but didn't provide guidance on net profitability. Adjusted EBITDA excludes stock-based compensation, restructuring charges, and other non-cash items, making it a less stringent measure than GAAP net income.

Constellation Brands provides liquidity but not indefinite runway.

Canopy Growth's largest shareholder, Constellation Brands, holds a 37% equity stake and has extended multiple credit facilities to the cannabis company since 2018. In March 2026, Constellation converted CAD $200 million of debt into equity at a share price of CAD $1.85, diluting existing shareholders by 8%. The beverage giant has signaled it won't provide additional capital injections beyond the current credit line, which matures in December 2027.

Without a fresh equity raise or debt refinancing, Canopy Growth's cash position of CAD $180 million as of June 30, 2026, gives the company roughly nine months of runway at current burn rates. A reverse stock split is off the table. Alternative financing plans remain undisclosed.

International revenue is a bright spot but too small to offset domestic headwinds.

Canopy Growth's medical cannabis exports to Germany, Australia, and Poland generated CAD $22 million in Q2 2026, up 18% year-over-year. The company holds import licenses from BfArM in Germany and the Therapeutic Goods Administration in Australia, positioning it to serve two of the world's largest medical cannabis markets. International sales still represent only 22% of total revenue, insufficient to offset the 6% decline in Canadian adult-use sales.

Germany's recreational legalization framework, which took effect in April 2024, hasn't yet opened retail channels to foreign producers. Canopy's German subsidiary, Spektrum Therapeutics, operates under medical-only licenses and can't participate in the social club model that dominates Germany's current legal market. Full commercial retail isn't expected until 2028 at the earliest, according to the German Ministry of Health.

Equity analysts set price targets contingent on profitability milestones.

Eight equity analysts covering Canopy Growth maintain a consensus rating of Hold, with price targets ranging from CAD $1.50 to CAD $3.00 per share. The stock closed at CAD $1.92 on July 24, 2026, down 38% year-to-date. Analysts at Canaccord Genuity and Stifel both cite the need for two consecutive profitable quarters before upgrading to a Buy rating.

The market is pricing in significant execution risk. Canopy's enterprise value-to-sales ratio of 0.8x sits below the Canadian LP peer average of 1.2x, reflecting investor skepticism about the company's ability to convert revenue into profit. Tilray Brands trades at 1.6x sales. It's posted three consecutive profitable quarters.

We'll be watching Q3 2026 earnings in late September.

Investors will watch whether Canopy Growth can deliver on its adjusted EBITDA breakeven target when it reports Q3 results in late September. The company hasn't provided full-year revenue guidance, making quarterly results the primary data point for gauging turnaround progress. For full background on this story, see the CannIntel topic hub on Canopy Growth stock analysis.